The federal Project Grant award of $473,463 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports the Inclusive Cancer Care Research Equity (ICCARE) for Black Men Consortium, which is investigating cancer care and outcomes for Black men in Nigeria. Covenant University, a private for-profit educational institution in Ota, Nigeria, is the primary awardee and will conduct this research over the period of September...
The U.S. National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Nuago Therapeutics Inc., a small disadvantaged business in Chicago, IL. The grant supports the "Development of a DISE-Inducing, Short RNA Therapeutic to Treat Ovarian Cancer" project from June 2025 to May 2026. The project aims to advance cancer treatment by developing an innovative short RNA therapeutic to target and treat ovarian cancer, which...
The National Cancer Institute (NCI) awarded a $147,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to Baylor College of Medicine. The grant, awarded on December 1, 2025, will support a novel immune tolerization strategy called RECON to investigate the trade-offs between oncogene pathogenicity and immunogenicity. The project aims to uncouple an oncogene's pathogenic potential from its immunogenic properties, enabling the dissection of genetic and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $196,267 in funding to the University of California, Irvine to support a range of activities focused on advancing cancer prevention and therapeutic strategies across NCI-sponsored clinical trial networks. Key objectives include: Providing leadership roles on NCI committees to promote diversity in clinical trial development and patient enrollment Serving as Principal Investigator...
This $1,072,500 Project Grant award from the National Institute of General Medical Sciences (NIGMS) Biomedical Research and Research Training Program (CFDA 93.859) supports cancer research in Oklahoma. The primary objectives are to advance cancer research, enhance core research facilities, foster cross-disciplinary collaboration, and promote translational research at the University of Oklahoma Health Sciences Center. The grant, awarded on August 10, 2024 with an ultimate completion date of...
This $284,201.82 Project Grant from the National Cancer Institute, a division of the Department of Health and Human Services, will fund research into malignant cell engagement in immune circuits of human colorectal cancer. The Broad Institute, Inc. will utilize single cell RNA sequencing data from over 700,000 malignant, immune, and stromal cells from colorectal cancer patients to test the hypothesis that malignant cells expressing interferon-stimulated genes acutely promote anti-tumor immunity,...
This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $546,625.00 to the University of Pittsburgh to develop an improved immunochemotherapy treatment for metastatic colorectal cancer (mCRC). The key objectives are to: Develop and characterize a nanoparticle carrier that can co-deliver small interfering RNA (siRNA) targeting the IRHOM1 protein and a chemotherapy agent (CPT-SAHA) to mCRC tumors. Investigate the...
This $334,233 federal Project Grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program supports a research project conducted by the University of South Carolina to examine disparities in cancer care and outcomes. The project aims to: Describe and compare patterns of novel targeted therapies for lung and colon cancer by race, socioeconomic status, and urban/rural designation, and their impact on survival disparities. Describe and...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $406,611.00 to the University of Texas Health Science Center at Houston to conduct research on the role and therapeutic targeting of the GPR56 protein in colorectal cancer. The key objectives are to: Characterize the role and signaling mechanisms of GPR56 in colorectal cancer stem cells and metastasis using patient-derived organoids. Develop and evaluate highly potent...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) supports research to profile patient-specific tumor-microbiome interactions and conduct quantitative molecular analyses to elucidate microbiome-mediated modulation of immune checkpoint molecules in mismatch repair-proficient and microsatellite-stable colorectal tumors. The $400,890 award, effective March 1, 2025 through February 28, 2028, will utilize patient-derived tumor or normal organoids in a...
This federal Project Grant award, valued at $1,149,273.00 and issued by the National Cancer Institute (CFDA 93.399 - Cancer Control), aims to establish the Nigerian Immuno-Oncology Research (NOLA) Program. The key products and services to be delivered under this grant include:
Developing pilot data to guide future studies investigating the tumor microenvironment of colorectal cancer (CRC) in Nigerian patients.
Integrating a multi-disciplinary team and research projects focused on immuno-oncology in Nigerian and U.S. cancer patients.
Developing biobanks and databases of Nigerian CRC samples to support future immuno-oncology research.
The award includes sub-grants to the College of Medicine, University of Lagos and Obafemi Awolowo University in Nigeria to coordinate research activities, oversee data collection, and prepare samples. This project aims to address the significant disparities in CRC outcomes between Nigerian and U.S. patients by leveraging emerging immuno-oncology approaches and building research capacity in Nigeria.